

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

1 June 2023

Rights Issue Closure and Shortfall Notification

Zoono Group Limited (**Company**) (ASX: ZNO) advises that its recent Rights Issue closed on 26 May 2023 and raised \$1,087,230 before costs, with a shortfall balance of \$1,015,059. Zoono's Managing Director, Paul Hyslop, took up his full entitlement of 14,963,167 Shares (\$744,475), as did non-executive directors, Don Clarke and Elissa Hansen, together with the Company's Chief Financial Officer, Paul Ravlich, and Chief Operations Officer, Lew Mackinnon.

The Rights Issue was a pro-rata non-renounceable entitlement issue for one (1) New Share for every four (4) existing Shares held by eligible shareholders on the Record Date, at an issue price of \$0.05 per New Share, together with one (1) free New Option for every three (3) New Shares applied for and issued.

The results of the Rights Issue are as follows:

	Shares	Options
Total Number Offered:	42,045,771	14,015,257
Total Number Applied for:	21,744,592	7,248,264
Shortfall Number:	20,301,179	6,766,933

Allotment of the 21,744,592 New Shares and 7,248,264 Options is expected to occur tomorrow, 2 June 2023.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:**Zoono Group Limited**

Paul Hyslop

Group MD

M: +64 21 659 977

E: paul.hyslop@zoono.com

Paul Ravlich

Group CFO

M: +64 21 075 9176

E: paul.ravlich@zoono.com**About Zoono**

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'ZOONO molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the Company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com